<DOC>
	<DOCNO>NCT02220660</DOCNO>
	<brief_summary>The primary objective study compare systemic exposure BI 1744 BS CD 1857 XX ( active metabolite pro-drug BI 54903 XX ) steady state follow inhalation fix dose combination ( FDC ) BI 1744 CL plus BI 54903 XX ( ethanolic solution inhalation , EIS ) systemic exposure follow inhalation free dose combination BI 1744 CL ( aqueous solution inhalation , AIS ) BI 54903 XX ( EIS ) , respectively , administer once-daily via Respimat® Inhaler ( Respimat® A AIS Respimat® B EIS ) 14 day healthy volunteer . Secondary objective : compare exposure BI 1744 BS CD 1857 XX single dose BI 1744 CL/BI 54903 XX FDC free dose combination , respectively ; compare exposure BI 54903 XX single dose steady state multiple dos BI 1744 CL/BI 54903 XX fix dose combination free dose combination , respectively ; compare safety tolerability BI 1744 CL BI 54903 XX administer BI 1744 CL/BI 54903 XX fix dose combination free dose combination , respectively .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Fixed Dose Combination BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus Free Combination BI 1744 CL Via Respimat® A BI 54903 XX Via Respimat® B Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood pressure ( BP ) , Pulse rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age &gt; = 21 &lt; = 50 year BMI &gt; = 18.5 &lt; = 29.9 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day alcohol abuse ( 40 g/day ) Drug abuse Blood donation ( &gt; 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site For female Subjects : Pregnancy Positive pregnancy test No adequate contraception ( adequate contraception e.g . sterilization , intrauterine pessary ( IUP ) , oral contraceptive ) Inability maintain adequate contraception whole study period Lactation period Exclusion criterion specific study due know class side effect profile ß2mimetics inhaled corticosteroid : Asthma history pulmonary hyperreactivity Hyperthyreosis Allergic rhinitis need treatment Clinically relevant cardiac arrhythmia Bacterial viral infection lung include tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>